Clinical Trials
20 trialsNCT03789110 2026-04-28
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03650894 2026-04-13
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Providence Health & Services
Phase 2 Active not recruiting
NCT03546686 2026-03-27
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT06324240 2026-01-26
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
Phase 1 Recruiting
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT02833233 2024-10-23
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT03409198 2024-10-15
ICON
Oslo University Hospital
Phase 2 Completed
NCT06342037 2024-09-19
TONIC-3
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03815890 2024-05-30
BELLINI
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03818685 2024-02-12
BreastImmune03
Centre Leon Berard
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04132817 2022-12-02
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed
NCT03342417 2021-11-09
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
ExcellaBio LLC
Phase 2 Terminated
NCT02892734 2020-07-16
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Northwestern University
Phase 2 Terminated
NCT01986426 2018-10-03
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Completed
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT01502592 2016-01-05
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00060372 2013-03-27
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00083278 2012-04-27
Study of MDX-010 in Stage IV Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed